35 results
424B3
SHPH
Shuttle Pharmaceuticals Holdings Inc
22 Mar 24
Prospectus supplement
6:07am
cancer progression. The low number of drugs and biologic agents under investigation as radiation sensitizing agents highlights an unmet need for new … under investigation or approved, such as Vectibix® (panitumumab) from Amgen will be promoted as having radiation sensitizing properties, along
8-K
EX-10.2
SHPH
Shuttle Pharmaceuticals Holdings Inc
13 Feb 24
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
8:00am
in connection with the investigation, preparation, defense or settlement of any claim, action or proceeding, whether or not resulting in any liability
8-K
EX-10.1
SHPH
Shuttle Pharmaceuticals Holdings Inc
13 Feb 24
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
8:00am
with the knowledge and expectation that Buyer is relying thereon and the same shall not be affected by any investigation heretofore or hereafter made … hereto or thereto shall survive the Closing and shall not be deemed waived or otherwise affected by any investigation made or any knowledge acquired
8-K
EX-10.1
SHPH
Shuttle Pharmaceuticals Holdings Inc
5 Feb 24
Entry into a Material Definitive Agreement
4:25pm
that it and its counsel have had adequate opportunity to make whatever investigation or inquiry they deem necessary or desirable in connection with the subject
8-K
EX-10.1
x9y966be
30 Oct 23
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
5:14pm
8-K
EX-99.1
4d5fad
30 Oct 23
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
5:14pm
424B3
0az6ou6 uuszzn2
24 Aug 23
Prospectus supplement
2:00pm
8-K
EX-3.1
fefuhr
1 Nov 22
Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors
9:00am
DRS
p51ab5z1dqpz5ugusk5d
29 Sep 22
Draft registration statement
12:00am
424B4
lelns9 9m9z
31 Aug 22
Prospectus supplement with pricing info
6:16am
S-1/A
mdpez6
23 Jun 22
IPO registration (amended)
5:24pm